DataMEDS AI Secures Advanced Cancer Detection Platform to Expand Diagnostics
Pittsburgh, Thursday, 19 November 2026.
DataMEDS AI agreed to acquire a patented infrared blood-testing platform protected through 2034, aiming to accelerate commercial cancer screening by integrating proven technology with its diagnostic laboratory operations.
Strategic Acquisition Bolsters DataMEDS AI’s Diagnostic Arsenal
DataMEDS AI, Inc. (NASDAQ: MEDS) has finalized a transformative agreement to acquire the Total Biochemical Infrared Analysis (TBIA) cancer blood testing platform from the estate of Todos Medical Ltd., marking a significant milestone in the company’s expansion into AI-driven oncology diagnostics [1]. The proprietary spectroscopy technology, which leverages Fourier-transform infrared (FTIR) spectroscopy of blood plasma and peripheral blood mononuclear cells (PBMCs), is designed to enhance machine-learning models for detecting multiple cancer types [1][2]. Gerald Commissiong, Interim Co-CEO of DataMEDS AI, emphasized the platform’s untapped potential, stating, ‘The TBIA Cancer AI blood testing platform is a technology that was ahead of its time and now has the opportunity to truly flourish in the AI era’ [1][2].
Platform Validated in Europe, Patents Secure Long-Term Exclusivity
The TBIA platform previously obtained CE Marks in Europe for breast and colorectal cancer detection, underscoring its clinical viability [1]. Additionally, the technology is protected by issued patents in the U.S. and Europe, with exclusivity extending through at least 2034 [1][2]. This patent portfolio provides a critical competitive moat as DataMEDS AI integrates the platform into its CLIA-certified subsidiary, Helomics, Inc. [1]. Helomics, headquartered in Pittsburgh, Pennsylvania, operates one of the largest curated tumor biobanks in the world, housing over 70,000 primary tumor biopsies, including 50,000 gynecologic cancer samples collected over nearly three decades [3][5].
Regulatory Pathway and Commercialization Timeline
The acquisition transfers not only the TBIA platform but also its associated data, algorithms, and equipment to Helomics, where the proprietary technology will undergo rigorous data revalidation alongside traditional biopsy and imaging methods [1]. This process is designed to support the launch of a Laboratory Developed Test (LDT) ahead of planned FDA submissions, positioning DataMEDS AI at the forefront of regulatory-compliant AI diagnostics [1][2]. Following the acquisition, Helomics plans to collaborate with an oncologist network under IRB-approved protocols to source blood samples from patients undergoing tumor biopsy evaluations, including those billed under CPT codes 81535 and 81536 for the ChemoFx® Assay [3][5]. Gerald Commissiong noted, ‘We are excited to have identified our first partner that begins the process of monetizing the unique resources in our lab and will help us unlock the tremendous value resident in one of the world’s largest curated biobanks’ [3].
Broader Strategic Vision and Market Context
The acquisition of the TBIA platform aligns with DataMEDS AI’s broader strategy to integrate advanced diagnostics with AI-driven healthcare solutions, as outlined in its Q4 2026 corporate outlook released on November 18, 2026 [2]. The company, which recently rebranded from Wellgistics Health, Inc., has been focusing on expanding patient flow to support research and development, including initiatives like the ‘Health Lives Here’ program in collaboration with a Florida-based HMO [2][4]. The global cancer diagnostics market, valued at USD 189.19 billion in 2024, is projected to reach USD 386.19 billion by 2035, reflecting the growing demand for innovative and scalable diagnostic technologies [1][3]. DataMEDS AI’s stock (MEDS) has experienced significant volatility, trading at $0.7277 at the close of November 19, 2026, with a market capitalization of approximately $4.166 million, highlighting both the high-risk and high-reward nature of its strategic bets [6].
Financial and Operational Implications
The TBIA acquisition comes on the heels of DataMEDS AI’s settlement of litigation related to the Wellgistics, LLC Membership Purchase Interest Agreement, which eliminated approximately $19 million in liabilities from its balance sheet [7][8]. As part of the settlement, the company repurchased and retired 364,099 common shares and paid $450,000 in cash, signaling a concerted effort to streamline operations and strengthen its financial position [7][8]. Additionally, DataMEDS AI entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc., on November 17, 2026, to offer and sell shares of its common stock under its shelf registration statement on Form S-3 (File No. 333-295078), providing flexibility for future capital raising [7][8][9]. The company’s shares trade on the Nasdaq Capital Market under the ticker MEDS, with a 52-week range of $0.4930 to $33.1500, underscoring the volatility of its stock performance [6].
Sources
- www.newswire.com
- www.stocktitan.net
- markets.businessinsider.com
- www.webdisclosure.com
- finance.yahoo.com
- za.investing.com
- ng.investing.com
- au.investing.com